Cross sections of the 226Ra(p,xn) reactions relevant for 225Ac production

IF 3.6 4区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Nuclear medicine and biology Pub Date : 2025-01-21 DOI:10.1016/j.nucmedbio.2025.108995

Ondřej Lebeda, Kateřina Ondrák Fialová, Lukáš Ondrák, Jaroslav Červenák, Jan Ráliš, Jan Štursa

引用次数: 0

Abstract

Limited availability constrains the implementation of ²²⁵Ac, the most promising α emitter for targeted therapy, in clinical practice. Proton activation of ²²⁶Ra is one of few realistic solutions to this problem. We have therefore measured cross sections of relevant ²²⁶Ra(p,xn) nuclear reactions in the energy range of 12.0 to 17.2 MeV. The obtained results allowed us to deduce the yield of ²²⁴Ac, ²²⁵Ac, and ²²⁶Ac. The consequences of our data to predictions of production capacity and radionuclidic purity of ²²⁵Ac are thoroughly discussed, and their comparison with previous measurements and with the prediction of the TALYS 1.96 nuclear reaction model code run with default parameters are provided.

Abstract Image

查看原文本刊更多论文

与225Ac生产相关的226Ra（p,xn）反应截面。

在临床实践中，有限的可用性限制了最有希望用于靶向治疗的α发射器225Ac的实施。226Ra的质子活化是为数不多的解决这个问题的现实方法之一。因此，我们测量了能量范围为12.0至17.2 MeV的相关226Ra（p,xn）核反应的截面。得到的结果使我们能够推断出224Ac、225Ac和226Ac的产率。我们的数据对预测225Ac的生产能力和放射性核素纯度的影响进行了深入的讨论，并与以往的测量结果以及与默认参数运行的TALYS 1.96核反应模型代码的预测结果进行了比较。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nuclear medicine and biology 医学-核医学

CiteScore

6.00

自引率

9.70%

发文量

479

审稿时长

51 days

期刊介绍： Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized. These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field. Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.